ZA914919B - Method of treating prostatic adenocarcinoma - Google Patents

Method of treating prostatic adenocarcinoma

Info

Publication number
ZA914919B
ZA914919B ZA914919A ZA914919A ZA914919B ZA 914919 B ZA914919 B ZA 914919B ZA 914919 A ZA914919 A ZA 914919A ZA 914919 A ZA914919 A ZA 914919A ZA 914919 B ZA914919 B ZA 914919B
Authority
ZA
South Africa
Prior art keywords
prostatic adenocarcinoma
treating prostatic
alpha
reductase inhibiting
treating
Prior art date
Application number
ZA914919A
Other languages
English (en)
Inventor
Randal Keith Johnson
Keith Johnson Randal
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24173248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA914919(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of ZA914919B publication Critical patent/ZA914919B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA914919A 1990-06-27 1991-06-26 Method of treating prostatic adenocarcinoma ZA914919B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/544,709 US5300294A (en) 1990-06-27 1990-06-27 Method of treating prostatic adenocarcinoma

Publications (1)

Publication Number Publication Date
ZA914919B true ZA914919B (en) 1992-07-29

Family

ID=24173248

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA914919A ZA914919B (en) 1990-06-27 1991-06-26 Method of treating prostatic adenocarcinoma

Country Status (15)

Country Link
US (2) US5300294A (ja)
EP (1) EP0536282B1 (ja)
JP (5) JP2702280B2 (ja)
KR (1) KR100209825B1 (ja)
AT (1) ATE151635T1 (ja)
AU (1) AU650033B2 (ja)
CA (1) CA2084775C (ja)
DE (1) DE69125714T2 (ja)
DK (1) DK0536282T3 (ja)
ES (1) ES2100952T3 (ja)
GR (1) GR3024064T3 (ja)
HK (1) HK1006412A1 (ja)
IE (1) IE81134B1 (ja)
WO (1) WO1992000010A1 (ja)
ZA (1) ZA914919B (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5239075A (en) * 1991-08-21 1993-08-24 Eli Lilly And Company Process for the preparation of benzo (f) quinolinones
CA2084799C (en) 1991-12-17 2003-01-28 Glenn J. Gormley Method of prevention of prostatic carcinoma with 17 beta-n-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1 -en-3-ones
US5994362A (en) * 1992-03-11 1999-11-30 Merck & Co., Inc. Method of treatment for prostatic cancer
WO1993023420A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS
AU674145B2 (en) * 1992-05-20 1996-12-12 Merck & Co., Inc. New 17-ester, amide, and ketone derivatives of 3-oxo-4-azasteroids as 5a-reductase inhibitors
GB9210880D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Corp Compounds
GB9213901D0 (en) * 1992-06-30 1992-08-12 Smithkline Beecham Corp Compounds
CN1133005A (zh) * 1993-09-03 1996-10-09 史密丝克莱恩比彻姆公司 稳定的片剂
US5763490A (en) * 1994-09-20 1998-06-09 University Of South Carolina Treating prostate cancer with tartrate ions
US5578724A (en) * 1994-09-20 1996-11-26 Eli Lilly And Company Process for preparation of benzo[f]quinolinones
US5635197A (en) * 1995-03-21 1997-06-03 Eli Lilly And Company Treatment and prevention of prostatic cancer metastasis
US5629007A (en) * 1995-03-21 1997-05-13 Eli Lilly And Company Method of preventing prostatic cancer development
JPH09172979A (ja) * 1995-12-27 1997-07-08 Ajinomoto Co Inc 新規リン酸アミノ酸複合塩及び制酸剤を含有する反すう動物用飼料添加組成物
US6093722A (en) 1997-02-26 2000-07-25 Sankyo Company, Limited Method for treating prostate cancer
GB9717444D0 (en) * 1997-08-19 1997-10-22 Glaxo Group Ltd Pharmaceutical composition
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
US6365181B1 (en) 2000-04-20 2002-04-02 Gattefosse Corporation Thixatropic gelatin carrier composition
US20060084704A1 (en) * 2004-01-28 2006-04-20 Charles Shih Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
EP1765346A4 (en) * 2004-01-28 2008-10-15 Androscience Corp STRENGTHENING ANTI-ANDROGEN ACTIVITY BY COMBINING INHIBITORS TARGETING DIFFERENT STEROID DEPENDENCE GENE ACTIVATION PATH PATTERNS, AND USES THEREOF
US9000222B2 (en) 2007-01-08 2015-04-07 Androscience Corporation Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
US8710272B2 (en) 2007-01-08 2014-04-29 Androscience Corporation Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
US8236852B2 (en) 2007-01-08 2012-08-07 Androscience Corporation Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof
US9446127B2 (en) 2007-07-31 2016-09-20 Androscience Corporation Compositions including androgen receptor degradation (ARD) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
AU2010210422A1 (en) 2009-02-05 2011-08-18 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
EP4066841A1 (en) 2013-03-14 2022-10-05 University of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
SG11201600525XA (en) 2013-08-12 2016-02-26 Tokai Pharmaceuticals Inc Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US10585101B2 (en) 2016-03-10 2020-03-10 Wavesense, Inc. Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
JPS63203625A (ja) * 1987-02-19 1988-08-23 Kao Corp ５α−リダクタ−ゼ阻害剤
DE3888378T2 (de) * 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
ZA883034B (en) * 1987-04-29 1989-03-29 Smithkline Beckman Corp Steroid 5-alpha-reductase inhibitors
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
US5041433A (en) * 1987-04-29 1991-08-20 Smithkline Beecham Corporation 11-keto or hydroxy 3,5-diene steroids as inhibitors of steriod 5-α-reductase
US4882319A (en) * 1988-12-23 1989-11-21 Smithkline Beckman Corporation Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4970205A (en) * 1988-12-23 1990-11-13 Smithkline Beecham Corporation Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4937237A (en) * 1988-12-23 1990-06-26 Smithkline Beckman Corporation Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase
US4946834A (en) * 1988-12-23 1990-08-07 Smithkline Beecham Corporation Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors
CA2062792C (en) * 1989-07-07 2006-03-21 Fernard Labrie Treatment of androgen-related diseases
CA2023157A1 (en) * 1989-08-21 1991-02-22 Gary H. Rasmusson 17 beta-acyl-4-aza-5 alpha-androst-1-ene-3-ones as 5 alpha-reductase inhibitors
US5032586A (en) * 1989-08-24 1991-07-16 Smithkline Beecham Corporation 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase
US5137882A (en) * 1990-06-11 1992-08-11 Holt Dennis A Steroidal 3-acetic acid derivatives as 5-alpha-reductase inhibitors
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma

Also Published As

Publication number Publication date
JP2007063296A (ja) 2007-03-15
US5496556A (en) 1996-03-05
GR3024064T3 (en) 1997-10-31
AU8207691A (en) 1992-01-23
EP0536282A1 (en) 1993-04-14
KR100209825B1 (ko) 1999-07-15
DE69125714T2 (de) 1997-10-23
EP0536282A4 (en) 1993-05-05
DE69125714D1 (de) 1997-05-22
JP2002308776A (ja) 2002-10-23
IE81134B1 (en) 2000-03-22
JPH05508155A (ja) 1993-11-18
JP2000309536A (ja) 2000-11-07
CA2084775A1 (en) 1991-12-28
ES2100952T3 (es) 1997-07-01
US5300294A (en) 1994-04-05
WO1992000010A1 (en) 1992-01-09
HK1006412A1 (en) 1999-02-26
DK0536282T3 (da) 1997-10-27
KR930701175A (ko) 1993-06-11
AU650033B2 (en) 1994-06-09
JPH1081625A (ja) 1998-03-31
ATE151635T1 (de) 1997-05-15
JP2702280B2 (ja) 1998-01-21
EP0536282B1 (en) 1997-04-16
CA2084775C (en) 2003-04-15
IE912233A1 (en) 1992-01-01

Similar Documents

Publication Publication Date Title
ZA914919B (en) Method of treating prostatic adenocarcinoma
ZA955466B (en) Stereochemical wortmannin derivatives
ZA981080B (en) Bicyclic inhibitors of protein farnesyl transferase
EP0674513A1 (en) COMPOUNDS INHIBITING RETROVIRAL PROTEASES.
DE69230857D1 (de) Steroid-Sulfatase hemmende Verbindungen
MX9707192A (es) Compuestos triciclicos de carbamato, utiles para la inhibicion de la funcion de la proteina g y paratratamiento de enfermedades proliferativas.
NO20044458L (no) Anvendelse av en ringsystemforbindelse for fremstilling av et medikament
YU82304A (sh) Kristalni 3,4,4-trisupstituisani-piperidinil-n-alkilkarboksilati, intermedijeri i postupak za dobijanje
ES2125495T3 (es) 4-aza-androstano 16 sustituidos inhibidores de la isoenzima 5-alfa-reductasa 1.
MX9602861A (es) Mezcla estabilizante sinergistica.
UA32529C2 (uk) Спосіб очистки стічних вод та пристрій для його здійснення
EP0646007A1 (en) NEW DELTA-17 AND DELTA-20 UNSATURATED AND SATURATED 17 - g (b) -SUBSTITUTED-4-AZA-5-g (a) -ANDROSTAN-3-ON COMPOUNDS AS INHIBITORS OF 5-ALPHA REDUCTASE.
NO910884L (no) Utstyr for fjernstyrt innsetting av sementeringsplugger iundervannsborete broenner.
TW258728B (ja)
EP0600149A3 (en) Method of making a self aligned static induction transistor.
TW325997B (en) Pharmaceutical composition for preventing and treating retinal diseases
NO912782D0 (no) Fremgangsmaate for behandling av skrap av legeringer av sjeldne jordmetaller/overgangsmetaller.
FR2498607B1 (ja)
IL133392A0 (en) Benzo (5, 6) cyclohepta (1, 2b) pyridine derivatives useful for inhibition of farnesyl protein transferase
SU957744A1 (ru) Трансформаторный плазмотрон
NZ314002A (en) A method of inhibiting inflammatory cytokine formation using polyprenyl derivatives
GR79051B (ja)
SU1051981A1 (ru) Способ защиты от коррозии ледоколов и судов ледового плавания
HU903835D0 (en) Multistep combined punching torpedo- and rock treating process for the opening of deep drillings big blasting
ZA922012B (en) New method of treatment for prostatic cancer